Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: John Carragher who wrote (446)	8/12/1998 12:56:00 PM
From: John Carragher	Respond to of 798

Home - Yahoo! - Help Yahoo! Games - play online poker, chess, bridge, backgammon, spades ... [ Business \| US Market \| By Industry \| IPO \| AP \| S&P \| International \| PRNews \| BizWire ] Wednesday August 12, 8:29 am Eastern Time Company Press Release SOURCE: Boston Scientific Corporation Boston Scientific Corporation Receives FDA Approval For The NIR Coronary Stent NATICK, Mass., Aug. 12 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX - news) announced today U.S. Food & Drug Administration (FDA) approval and immediate market release of the NIR ON(TM) Ranger(TM) and the NIR ON(TM) Ranger(TM) with SOX(TM) over-the-wire balloon expandable premounted coronary stent systems for the treatment of coronary artery disease. The NIR(TM) stent will be available in lengths of 9, 16, 25 and 32mm and diameters of 2.5, 3.0, 3.5 and 4.0mm. Coronary stents prop open arteries to facilitate blood flow to the heart. The patented NIR stent is based on a proprietary transformable geometry(TM) design which allows for flexibility during insertion and rigidity after implantation. The patented SOX stent securement system is a unique feature that enhances safety in delivering the stent. The NIRVANA clinical trial served as the basis for FDA approval. NIRVANA included a randomized trial comparing the NIR stent to a stainless steel balloon expandable stent, as well as registries for abrupt and threatened closure, and the treatment of saphenous vein grafts. The NIR stent performed well in all aspects of the NIRVANA trial. The NIR stent was developed and is manufactured by Medinol Ltd. of Tel Aviv, Israel. Boston Scientific has an exclusive worldwide license to market and distribute the NIR stent. Pete Nicholas, Chairman and Chief Executive Officer of Boston Scientific, said, ''The introduction of the NIR stent platform in the U.S. market clearly signals our commitment to leadership in coronary stenting. I would like to congratulate the Medinol team for their success in designing and developing the stent. In particular, I commend their exceptional management of the NIRVANA clinical trial.'' Dr. Judith Richter, Chief Executive Officer of Medinol Ltd., said, ''We believe the NIR is the premier coronary stent platform in the world. In conjunction with our partners at Boston Scientific, we are pleased to make available the NIR stent for the treatment of patients in the United States.'' Medinol Ltd., a private company, is a pioneer in innovative technology development and in the manufacture of stenting solutions for a variety of medical applications. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. SOURCE: Boston Scientific Corporation More Quotes and News: Boston Scientific Corp (NYSE:BSX - news) Related News Categories: medical/pharmaceutical Help Copyright c 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information. Questions or Comments?